This article was originally published in The Gray Sheet
Executive SummaryAcquisition of Laser Skin Toner for roughly 1.7 mil. shares of BioLase stock is valued at about $6 mil. LST's laser "no-incision facelift" and stretch-mark removal system, which is currently pending FDA clearance, is anticipated to round out BioLase's newly formed Aesthetic Division and complement its DermaLase hydrokinetic system and Lazer ToothBrush tooth-whitening system, BioLase states
You may also be interested in...
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.
Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.